Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — ASX SMIDcaps Conference, Sydney 2025
22 slides from Optiscan Imaging's conference presentation, Sep 24, 2025
Slide 1: The new standard in digital pathology and precision surgery
The new standard in digital pathology and precision surgery. Optiscan Imaging Ltd. (ASX:OIL) ASX SMIDcaps Conference, Sydney 24 September 2025
Slide 2: Dr Camile Farah, CEO & Managing Director
Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director Optiscan Imaging Ltd (ASX:OIL) ceo@optiscan.com /company/Optiscan www.optiscan.com
Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) on 19 September 2025 and approved for market release by the Board of Optiscan. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contai
Slide 4: Medicine has moved into the 21st century….
Medicine has moved into the 21st century….
Slide 5: …but Pathology is stuck in the 19th
…but Pathology is stuck in the 19th
Slide 6: Pathology - the weakest link in modern medicine
Pathology - the weakest link in modern medicine • Every field of medicine relies on pathology — yet it remains analogue, slow, and reactive. • Surgeons operate partly blind, without real-time tissue assessment. • Repeat procedures and delayed results create more risk, overload hospitals, delay treat
Slide 7: From bottleneck to breakthrough
From bottleneck to breakthrough Imagine pathology that’s real-time, digital, and at the point of care! Imagine doctors diagnosing conditions on the spot without biopsies or delays! Imagine surgeons treating cancers completely first time, every time! Imagine pathologists seeing cells live during the
Slide 8: We see what others don't
We see what others don’t Optiscan - a global medical technology company leading the transformation of digital pathology and precision surgery ASX: OIL Melbourne $70m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products Agile Office & Plant Ce
Slide 9: The digital leap in pathology
The digital leap in pathology • Pathology reimagined: From analogue slides to instant, live images captured at the point of care. • End-to-end workflow: A seamless continuum linking surgery, pathology, remote consultation, and AI. • Better outcomes: First-time margin clearance, faster treatment deci
Slide 10: One technology, many markets
One technology, many markets • Medical: real-time surgery, digital pathology, robotic integration. • Veterinary: oncology, minimally invasive procedures, point of care. • Telepathology and AI/ML: remote consultation, digital workflows, decision support. • Life sciences: live, longitudinal imaging, r
Slide 11: The next era of medicine
The next era of medicine Clinical Device Family Vision + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecular Surgery Horizontall
Slide 12: Devices with impact
Devices with impact ViewnVivo® InSpecta InVivage® InVue® InForm (Life sciences) (Veterinary) (Oral) (Surgery) (Pathology) Clinical Testing & Regulatory Submissions Underway
Slide 13: Imaging in action
Imaging In action Optiscan’
Slide 14: Clarity no one else can deliver
Clarity no one else can deliver Invasive Breast Cancer • Unique capability: See living cells in the body, in real time, with resolution >1000x CT/MRI. H&E CLE • Protected by IP and expertise: Decades of R&D, patent-protected platform, high barrier to replicate. • Digital-native advantage: No slides,
Slide 15: Telepathology & AI/ML solutions
Telepathology & AI/ML solutions Instantaneous diagnostic capability of pre-cancer and cancer with AI solutions Enabling digital pathology whenever, wherever
Slide 16: From invention to commercialisation
From invention to commercialisation Optiscan is on a transformation journey; from OEM to pure play digital solutions provider. Optiscan now sits at a significant juncture; crossing from product development to commercial adoption. Phase 1: Phase 2: Phase 3: Core foundation Strategic transformatio
Slide 17: Secure financial footing
Secure financial footing R&D Expense & New Devices Revealed Revenue and Other Income Cash on Hand R&D Expense (LHS) New Devices Revealed (RHS) $M $M $M Revenue Other Income 20 6 2 5 4 15 4 3 1 10 2 2 5 1 - - - - FY23 FY24 FY25 FY23 FY24 FY25 FY24 FY25 Sep25 (unaudited) 3 new devices revealed over la
Slide 18: Product pipeline
Product pipeline Application Stage Collaborators Veterinary IDEATION PROTOTYPING PRECLINICAL CLINICAL 2025-2026 REGULATORY 2026 LAUNCH 2026 MONITORING Surgical CLINICAL REGULATORY LAUNCH IDEATION PROTOTYPING PRECLINICAL MONITORING 2025-2026 2026 2027 Hardware Pathology IDEATION PROTOTYPING PRECLINIC
Slide 19: Scalable business model
Scalable business model Revenue model: • Hardware – devices sold into clinics, hospitals, pathology labs and veterinary practices. CAPEX – High gross margins. • Software – SaaS subscription revenue from telepathology and AI/ML solutions. • Consumables - recurring revenue from single-use sterile disp
Slide 20: Investment thesis
Investment thesis Value Proposition Revolutionary Patent- Versatility of Platform & Diversified Hardware & Limitless Growth Protected Technology Global Applications Software Offerings Potential Market Differentiators & Investment Thesis Competitive Revenue + Recurring High Barrier To Advantage in Sc
Slide 21: A category-defining opportunity
A category-defining opportunity This is the leap from analogue to digital, from delay to immediacy - and Optiscan is making it possible. • Revolutionary technology - the only platform delivering high resolution, real-time, sub-cellular, live microscopic imaging. • Multi-market growth – veterinary, p
Slide 22: Dr Camile Farah, CEO & Managing Director
Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director Optiscan Imaging Ltd (ASX:OIL) ceo@optiscan.com /company/Optiscan www.optiscan.com
Optiscan Imaging — ASX SMIDcaps Conference, Sydney 2025 on 6ix